TriSalus Life Sciences logo
TLSITriSalus Life Sciences
Trade TLSI now
TriSalus Life Sciences primary media

About TriSalus Life Sciences

TriSalus Life Sciences (NASDAQ:TLSI) is a pioneering biotechnology firm committed to transforming the treatment of solid tumors through integrated therapeutic and drug delivery solutions. Focusing on innovative research and development, TriSalus is dedicated to advancing technologies that enhance the delivery of immunotherapies and drugs directly to the site of disease, especially targeting liver and pancreatic cancers. The company's projects include developing proprietary Pressure-Enabled Drug Delivery (PEDD) technology and SD-101, an immunotherapy agent, aiming to improve outcomes for patients battling these hard-to-treat cancers. TriSalus's objective is to overcome the limitations of current treatments by enhancing drug concentrations at the tumor site, thereby improving therapeutic efficacy and patient survival rates.

What is TLSI known for?

Snapshot

Public US
Ownership
2010
Year founded
106
Employees
Westminster, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Westminster, US

Produtos e/ou serviços de TriSalus Life Sciences

  • Pressure-Enabled Drug Delivery (PEDD) technology aims to improve the delivery of therapeutics to solid tumors.
  • SD-101, an investigational Toll-like receptor 9 (TLR9) agonist for treating solid tumors.
  • Immunotherapy programs focus on leveraging the immune system to fight cancer, particularly in the liver and pancreas.
  • Drug development portfolio targeting diseases with high unmet medical need, focusing on oncology and liver diseases.
  • Life sciences research collaborations aimed at discovering and advancing innovative treatments for cancer.
  • Technology platforms designed to enhance the administration and effectiveness of oncology therapies.

equipe executiva do TriSalus Life Sciences

  • Ms. Mary T. Szela B.S.N., M.B.A.CEO, President & Director
  • Ms. Jodi DevlinChief of Clinical Strategy & Operations
  • Mr. David B. PatienceChief Financial Officer
  • Ms. Lori Ann SantamariaVice President of Operations
  • Andrea MarassoVice President of Marketing
  • Ms. Jennifer L. Stevens J.D.Chief Regulatory Officer
  • Dr. Richard B. Marshak M.B.A., VMDChief Commercial Officer
  • Dr. Bryan F. Cox Ph.D.Chief of Research
  • Mr. James E. YoungSecretary & Treasurer
  • Dr. Richard MarshallMedical Director

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.